TrialAntimicrobial agents and chemotherapy2017

Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.

Julie H Ishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.